MXPA03001210A - Uso de antagonista del receptor 5-ht4 en la fabricacion de un medicamento para la profilaxis o tratamiento de fibrilacion atrial. - Google Patents
Uso de antagonista del receptor 5-ht4 en la fabricacion de un medicamento para la profilaxis o tratamiento de fibrilacion atrial.Info
- Publication number
- MXPA03001210A MXPA03001210A MXPA03001210A MXPA03001210A MXPA03001210A MX PA03001210 A MXPA03001210 A MX PA03001210A MX PA03001210 A MXPA03001210 A MX PA03001210A MX PA03001210 A MXPA03001210 A MX PA03001210A MX PA03001210 A MXPA03001210 A MX PA03001210A
- Authority
- MX
- Mexico
- Prior art keywords
- prophylaxis
- treatment
- mammal
- salt
- pharmaceutically acceptable
- Prior art date
Links
- 238000011321 prophylaxis Methods 0.000 title abstract 4
- 238000011282 treatment Methods 0.000 title abstract 4
- 108091005482 5-HT4 receptors Proteins 0.000 title 1
- 230000002526 effect on cardiovascular system Effects 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 6
- 241000124008 Mammalia Species 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 206010003130 Arrhythmia supraventricular Diseases 0.000 abstract 1
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000001746 atrial effect Effects 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000003523 serotonin 4 antagonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invencion se refiere al uso de un antagonista del receptor de 5-HT4 en la elaboracion de un medicamento para la profilaxis o tratamiento de remodelamiento atrial en un mamifero; preferiblemente, el antagonista es N-[(1-nbutil -4-piperidiniI) metil] -3, 4-dihidro-2H -[1, 3]oxazino [3, 2-1]indol- 10- carboxamida (SB 207266) o una sal farmaceuticamente aceptable de la misma; la invencion tambien se refiere al uso de SB 207266 o una sal farmaceuticamente aceptable de la misma en la elaboracion de un medicamento para el tratamiento o profilaxis de la fibrilacion atrial en un mamifero mediante la administracion al mamifero de un regimen de dosis diaria oral o parenteral de aproximadamente 0.2 mg a 1.0 mg de la SB 207266 o la sal de la misma por kg de peso corporal total (medida como la base libre); la invencion tambien se refiere al uso de SB 207266 o una sal farmaceuticamente aceptable de la misma en la profilaxis o tratamiento de arritmia atrial en un mamifero mediante la administracion de la SB 207266 o la sal de la misma en el primer dia a una dosis de carga de aproximadamente 1.2 a aproximadamente 2.0 veces la dosis diaria de mantenimiento, seguida por la administracion de la SB 207266 o sal a la dosis diaria de mantenimiento en dias subsecuentes.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0019410A GB0019410D0 (en) | 2000-08-07 | 2000-08-07 | Novel use |
GB0019524A GB0019524D0 (en) | 2000-08-08 | 2000-08-08 | Novel use |
GB0019523A GB0019523D0 (en) | 2000-08-08 | 2000-08-08 | Novel use |
GB0118919A GB0118919D0 (en) | 2001-08-02 | 2001-08-02 | Novel use |
GB0119022A GB0119022D0 (en) | 2001-08-03 | 2001-08-03 | Novel use |
PCT/GB2001/003544 WO2002011766A2 (en) | 2000-08-07 | 2001-08-07 | Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03001210A true MXPA03001210A (es) | 2004-08-12 |
Family
ID=27515972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03001210A MXPA03001210A (es) | 2000-08-07 | 2001-08-07 | Uso de antagonista del receptor 5-ht4 en la fabricacion de un medicamento para la profilaxis o tratamiento de fibrilacion atrial. |
Country Status (16)
Country | Link |
---|---|
US (3) | US20050032866A1 (es) |
EP (1) | EP1311295A2 (es) |
JP (2) | JP2004505930A (es) |
KR (1) | KR20030027010A (es) |
CN (1) | CN100413539C (es) |
AU (1) | AU781276B2 (es) |
BR (1) | BR0113073A (es) |
CA (1) | CA2418904A1 (es) |
CZ (1) | CZ2003366A3 (es) |
HU (1) | HUP0303075A3 (es) |
IL (1) | IL154279A0 (es) |
MX (1) | MXPA03001210A (es) |
NO (1) | NO20030588L (es) |
NZ (1) | NZ524108A (es) |
PL (1) | PL365048A1 (es) |
WO (1) | WO2002011766A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1476136T3 (da) * | 2002-02-14 | 2006-10-09 | Glaxo Group Ltd | Farmaceutisk præparat, der omfatter N-[(1-N-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indol-10-carboxamid eller salt, og fremgangsmåde derfor, der omfatter törgranulering |
GB0211230D0 (en) * | 2002-05-16 | 2002-06-26 | Medinnova Sf | Treatment of heart failure |
EP2366431A1 (en) * | 2010-03-19 | 2011-09-21 | Universitätsklinikum Hamburg-Eppendorf | Myeloperoxidase as a target in atrial fibrillation |
AU2015297705B2 (en) | 2014-07-30 | 2019-12-19 | Aetas Pharma Co., Ltd. | Optical isomer of 1,4-benzothiazepine-1-oxide derivative, and pharmaceutical composition prepared using same |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9009389D0 (en) * | 1990-04-26 | 1990-06-20 | Smith Kline French Lab | Treatment |
GB9103862D0 (en) * | 1991-02-25 | 1991-04-10 | Glaxo Group Ltd | Chemical compounds |
CZ283619B6 (cs) * | 1991-09-12 | 1998-05-13 | Smithkline Beecham P.L.C | Použití derivátů kyseliny benzoové pro výrobu farmaceutických prostředků, deriváty kyseliny benzoo vé, způsob jejich výroby a farmaceutické prostředky s jejich obsahem |
MA22647A1 (fr) * | 1991-09-14 | 1993-04-01 | Smithkline Beecham Plc | Procede de preparation d'un ester ou d'un amide d'un nouveau produit . |
US5852014A (en) * | 1992-03-12 | 1998-12-22 | Smithkline Beecham P.L.C. | Condensed indole derivatives as 5HT4 -receptor antagonists |
US5998409A (en) * | 1992-03-12 | 1999-12-07 | Smithkline Beecham Plc | Condensed indole derivatives as 5HT4 -receptor antagonists |
UA41311C2 (uk) * | 1992-03-12 | 2001-09-17 | Смітклайн Бічем Плс | КОНДЕНСОВАНІ ІНДОЛЬНІ ПОХІДНІ ЯК АНТАГОНІСТИ 5НТ<sub>4</sub> РЕЦЕПТОРА, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ |
GB9206989D0 (en) * | 1992-03-31 | 1992-05-13 | Glaxo Group Ltd | Chemical compounds |
MX9301837A (es) * | 1992-03-31 | 1994-02-28 | Glaxo Group Ltd | Ureas y fenilcarbamatos substituidos, proceso para su preparacion y composicion farmaceutica que los comprende. |
NZ251687A (en) * | 1992-03-31 | 1995-12-21 | Glaxo Group Ltd | Oxadiazol- and thiadiazol- phenylcarbamates and -phenylureas and pharmaceutical compositions thereof |
PL180336B1 (pl) * | 1993-05-26 | 2001-01-31 | Syntex Inc | Nowe 1-fenyloalkanony, bedace ligandami receptorów 5-HT, kompozycja farmaceutyczna zawierajaca 1-fenyloalkanony i sposób otrzymywania 1-fenyloalkanonów PL PL PL PL PL |
IL117438A (en) * | 1995-03-16 | 2001-12-23 | Lilly Co Eli | Indazolecarboxamides, their preparation and pharmaceutical compositions containing them |
TR199900321T2 (xx) * | 1996-08-16 | 1999-04-21 | Smithkline Beecham P.L.C. | N-(1-nbutil - 4 - piperidil)metil) -3,4-dihidro -2H- (1,3) oksazino (3.2A) indol-10- Karboksamit haz�rlama prosesi ve prosesteki tuzlar ve ara �r�nler. |
NZ535261A (en) * | 2000-08-08 | 2004-12-24 | Smithkline Beecham P | A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide |
-
2001
- 2001-08-07 PL PL01365048A patent/PL365048A1/xx unknown
- 2001-08-07 BR BR0113073-0A patent/BR0113073A/pt not_active IP Right Cessation
- 2001-08-07 NZ NZ524108A patent/NZ524108A/en unknown
- 2001-08-07 KR KR10-2003-7001797A patent/KR20030027010A/ko active Application Filing
- 2001-08-07 CZ CZ2003366A patent/CZ2003366A3/cs unknown
- 2001-08-07 US US10/344,075 patent/US20050032866A1/en not_active Abandoned
- 2001-08-07 AU AU76529/01A patent/AU781276B2/en not_active Ceased
- 2001-08-07 MX MXPA03001210A patent/MXPA03001210A/es unknown
- 2001-08-07 WO PCT/GB2001/003544 patent/WO2002011766A2/en active IP Right Grant
- 2001-08-07 CN CNB018169511A patent/CN100413539C/zh not_active Expired - Fee Related
- 2001-08-07 EP EP01954184A patent/EP1311295A2/en not_active Withdrawn
- 2001-08-07 CA CA002418904A patent/CA2418904A1/en not_active Abandoned
- 2001-08-07 IL IL15427901A patent/IL154279A0/xx unknown
- 2001-08-07 HU HU0303075A patent/HUP0303075A3/hu unknown
- 2001-08-07 JP JP2002517100A patent/JP2004505930A/ja active Pending
-
2003
- 2003-02-06 NO NO20030588A patent/NO20030588L/no not_active Application Discontinuation
-
2006
- 2006-09-20 US US11/533,542 patent/US20070015769A1/en not_active Abandoned
-
2007
- 2007-03-12 JP JP2007062210A patent/JP2007145869A/ja active Pending
- 2007-10-31 US US11/930,277 patent/US20080125422A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1311295A2 (en) | 2003-05-21 |
CA2418904A1 (en) | 2002-02-14 |
PL365048A1 (en) | 2004-12-27 |
KR20030027010A (ko) | 2003-04-03 |
HUP0303075A2 (hu) | 2003-12-29 |
CN1468112A (zh) | 2004-01-14 |
JP2004505930A (ja) | 2004-02-26 |
JP2007145869A (ja) | 2007-06-14 |
US20070015769A1 (en) | 2007-01-18 |
US20050032866A1 (en) | 2005-02-10 |
WO2002011766A2 (en) | 2002-02-14 |
HUP0303075A3 (en) | 2007-03-28 |
NZ524108A (en) | 2004-11-26 |
CN100413539C (zh) | 2008-08-27 |
NO20030588D0 (no) | 2003-02-06 |
NO20030588L (no) | 2003-04-03 |
IL154279A0 (en) | 2003-09-17 |
WO2002011766A3 (en) | 2002-08-01 |
AU7652901A (en) | 2002-02-18 |
AU781276B2 (en) | 2005-05-12 |
BR0113073A (pt) | 2004-06-22 |
US20080125422A1 (en) | 2008-05-29 |
CZ2003366A3 (en) | 2004-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kris et al. | Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin | |
US20020173505A1 (en) | Medicament | |
RU2005124363A (ru) | Твердые пероральные дозируемые формы валсартана | |
JPS6233204B2 (es) | ||
IL149496A (en) | Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract | |
CA2237582C (en) | Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors | |
CA2414111A1 (en) | Use of substituted indole compounds for increasing nitric oxide synthase activity | |
WO2002004418A2 (en) | Methods of inhibiting uterotrophic effects of estrogenic agents | |
CA2521182A1 (en) | Composition for improving cognition and memory | |
CA2593854A1 (en) | Organic compounds | |
MXPA03001210A (es) | Uso de antagonista del receptor 5-ht4 en la fabricacion de un medicamento para la profilaxis o tratamiento de fibrilacion atrial. | |
JP2575569B2 (ja) | 薬物従属症及び禁断症状の治療に関するグリシン/nmdaレセプターリガンドの用法 | |
NZ535261A (en) | A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide | |
ES2271229T3 (es) | Uso de antagonistas mglur5 para el tratamiento de condiciones pruriticas. | |
MY143571A (en) | Eplerenone crystalline form | |
MY138979A (en) | The use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions | |
WO2000076500A8 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
EP1061925A1 (en) | Combination of a gaba-a alpha 5 inverse agonist and a nicotinic agonist | |
MXPA01010340A (es) | Osanetant en el tratamiento de transtornos del humor. | |
GB2173399A (en) | Compositions containing 3-aminopropoxy-indoles for treating hypertension | |
US20030166667A1 (en) | Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient | |
JP2700799B2 (ja) | 鎮咳剤 | |
JP2004505930A5 (es) | ||
Westmead | Drugs for Parkinson’s disease | |
US3737541A (en) | Methods for the treatment of parkinsonism |